Biosplice Therapeutics Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
12. September 2024 07:00 ET
|
Biosplice Therapeutics, Inc.
Biosplice Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
Biosplice Announces Collaboration with Novo Nordisk in Diabetes
13. Juni 2024 06:00 ET
|
Biosplice Therapeutics, Inc.
Biosplice enters into a pre-clinical collaboration with Novo Nordisk to develop inhibitors of DYRK for diabetes
Biosplice Announces Upcoming Presentation of Successful OA-07 Phase 3 Long-Term Structure and Pain & Function Results for Lorecivivint for Treatment of Knee Osteoarthritis at OARSI Conference, and Completion and Preliminary Analysis of OA-21 Trial 12-Week Pain Results
18. April 2024 06:00 ET
|
Biosplice Therapeutics, Inc.
Presentation of OA-07 Phase 3 Long-Term Results for Lorecivivint and Preliminary Analysis of OA-21 Trial 12-Week Pain Results
Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program
08. März 2024 13:36 ET
|
Biosplice Therapeutics, Inc.
Biosplice announced today that its collaboration with The Roskamp Institute has been awarded funding by the US Department of Defense.
Biosplice Presents Successful Structure and Pain Results from Completed Phase 3 Long-Term Extension Clinical Trial for Lorecivivint for the Treatment of Knee Osteoarthritis
13. November 2023 06:00 ET
|
Biosplice Therapeutics, Inc.
Biosplice Therapeutics Inc. presents results of OA-07 Long-Term Extension Trial for its knee OA drug candidate, lorecivivint.
Biosplice Announces Interim Data from Phase 3 Long-Term Extension Clinical Trial in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial
15. Dezember 2022 09:00 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule...
Biosplice Announces Data from Recent Clinical Trials in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial
11. November 2022 09:00 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule...
Biosplice Therapeutics Announced New Clinical Data for Cirtuvivint (SM08502) at the European Society for Clinical Oncology Meeting
29. September 2022 09:00 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major...
First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial in Oncology
17. November 2021 09:15 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major...
Biosplice Licenses Development and Commercialization Rights for Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Haisco for the People’s Republic of China
15. September 2021 09:00 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO and CHENGDU, China, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase...